Altered Host MicroRNAomics in HIV Infections: Therapeutic Potentials and Limitations

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Aug 29

PMID 39201495

Authors

Maria J Santiago

Srinivasan Chinnapaiyan

Kingshuk Panda

Md Sohanur Rahman

Suvankar Ghorai

Irfan Rahman

Stephen M Black

Yuan Liu

Hoshang J Unwalla

Affiliations

Soon will be listed here.

Abstract

microRNAs have emerged as essential regulators of health and disease, attracting significant attention from researchers across diverse disciplines. Following their identification as noncoding oligonucleotides intricately involved in post-transcriptional regulation of protein expression, extensive efforts were devoted to elucidating and validating their roles in fundamental metabolic pathways and multiple pathologies. Viral infections are significant modifiers of the host microRNAome. Specifically, the Human Immunodeficiency Virus (HIV), which affects approximately 39 million people worldwide and has no definitive cure, was reported to induce significant changes in host cell miRNA profiles. Identifying and understanding the effects of the aberrant microRNAome holds potential for early detection and therapeutic designs. This review presents a comprehensive overview of the impact of HIV on host microRNAome. We aim to review the cause-and-effect relationship between the HIV-induced aberrant microRNAome that underscores miRNA's therapeutic potential and acknowledge its limitations.

References

Suvarna V, Deshmukh K, Murahari M . miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease. Front Pharmacol. 2022; 13:1034072. PMC: 9728483. DOI: 10.3389/fphar.2022.1034072. View

Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R . MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012; 109(31):E2110-6. PMC: 3412003. DOI: 10.1073/pnas.1209414109. View

van den Dries L, Claassen M, Groothuismink Z, van Gorp E, Boonstra A . Immune activation in prolonged cART-suppressed HIV patients is comparable to that of healthy controls. Virology. 2017; 509:133-139. DOI: 10.1016/j.virol.2017.06.014. View

. Human Immunodeficiency Virus (HIV). Transfus Med Hemother. 2016; 43(3):203-22. PMC: 4924471. DOI: 10.1159/000445852. View

Agosto L, Uchil P, Mothes W . HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy. Trends Microbiol. 2015; 23(5):289-95. PMC: 4417442. DOI: 10.1016/j.tim.2015.02.003. View

Laggerbauer B, Engelhardt S . MicroRNAs as therapeutic targets in cardiovascular disease. J Clin Invest. 2022; 132(11). PMC: 9151703. DOI: 10.1172/JCI159179. View

Crooke S, Vickers T, Liang X . Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020; 48(10):5235-5253. PMC: 7261153. DOI: 10.1093/nar/gkaa299. View

Xiao Q, Yan L, Han J, Yang S, Tang Y, Li Q . Metabolism-dependent ferroptosis promotes mitochondrial dysfunction and inflammation in CD4 T lymphocytes in HIV-infected immune non-responders. EBioMedicine. 2022; 86:104382. PMC: 9718960. DOI: 10.1016/j.ebiom.2022.104382. View

Van Rooij E, Purcell A, Levin A . Developing microRNA therapeutics. Circ Res. 2012; 110(3):496-507. DOI: 10.1161/CIRCRESAHA.111.247916. View

10.

Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin M, Cuzin L, Billaud E . Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. PLoS One. 2015; 10(10):e0141164. PMC: 4619009. DOI: 10.1371/journal.pone.0141164. View

11.

Li G, Piampongsant S, Faria N, Voet A, Pineda-Pena A, Khouri R . An integrated map of HIV genome-wide variation from a population perspective. Retrovirology. 2015; 12:18. PMC: 4358901. DOI: 10.1186/s12977-015-0148-6. View

12.

Ben Haij N, Leghmari K, Planes R, Thieblemont N, Bahraoui E . HIV-1 Tat protein binds to TLR4-MD2 and signals to induce TNF-α and IL-10. Retrovirology. 2013; 10:123. PMC: 4231456. DOI: 10.1186/1742-4690-10-123. View

13.

Chen C, Yang Z, Tang X . Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy. Med Res Rev. 2018; 38(3):829-869. DOI: 10.1002/med.21479. View

14.

Ingenito F, Roscigno G, Affinito A, Nuzzo S, Scognamiglio I, Quintavalle C . The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. Int J Mol Sci. 2019; 20(19). PMC: 6801421. DOI: 10.3390/ijms20194687. View

15.

Bayraktar R, Bertilaccio M, Calin G . The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors. Front Immunol. 2019; 10:1053. PMC: 6527596. DOI: 10.3389/fimmu.2019.01053. View

16.

Mbita Z, Hull R, Dlamini Z . Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets. Viruses. 2014; 6(8):3181-227. PMC: 4147692. DOI: 10.3390/v6083181. View

17.

Xu Z, Asahchop E, Branton W, Gelman B, Power C, Hobman T . MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology. PLoS Pathog. 2017; 13(6):e1006360. PMC: 5464672. DOI: 10.1371/journal.ppat.1006360. View

18.

Kim Y, Choi Y, Nam G, Kim I . Functionalized exosome harboring bioactive molecules for cancer therapy. Cancer Lett. 2020; 489:155-162. DOI: 10.1016/j.canlet.2020.05.036. View

19.

Herrera-Carrillo E, Liu Y, Berkhout B . Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors. Hum Gene Ther Methods. 2017; 28(4):177-190. PMC: 5568016. DOI: 10.1089/hgtb.2017.036. View

20.

Wang P, Qu X, Zhou X, Shen Y, Ji H, Fu Z . Two cellular microRNAs, miR-196b and miR-1290, contribute to HIV-1 latency. Virology. 2015; 486:228-38. DOI: 10.1016/j.virol.2015.09.016. View